Anixa Biosciences Inc's Comment on Sales, Marketing and Customers
The company develops CAR-T therapeutics, including lira-cel, which targets ovarian cancer by engineering killer T cells with Follicle Stimulating Hormone to recognize FSH-Receptor expressing cells. It collaborates with Moffitt Cancer Center, which has expertise in CAR-T technology and is conducting a Phase 1 clinical trial of lira-cel. The initial market focus is ovarian cancer, which represents 2% of female cancer cases but accounts for over 4% of cancer deaths among women in the U.S., with an estimated 21,000 new cases and 13,000 deaths projected in 2025. The company has also licensed technology from Cleveland Clinic to develop vaccines for triple-negative breast cancer and other breast cancers expressing the α-lactalbumin protein. The company plans to license lira-cel to a large pharmaceutical company for commercialization. Customers and collaborators mentioned include Cleveland Clinic, Moffitt Cancer Center, and Wistar.
Anixa Biosciences Inc’s Comment on Sales, Marketing and Customers
The company develops CAR-T therapeutics, including lira-cel, which targets ovarian cancer by engineering killer T cells with Follicle Stimulating Hormone to recognize FSH-Receptor expressing cells. It collaborates with Moffitt Cancer Center, which has expertise in CAR-T technology and is conducting a Phase 1 clinical trial of lira-cel. The initial market focus is ovarian cancer, which represents 2% of female cancer cases but accounts for over 4% of cancer deaths among women in the U.S., with an estimated 21,000 new cases and 13,000 deaths projected in 2025. The company has also licensed technology from Cleveland Clinic to develop vaccines for triple-negative breast cancer and other breast cancers expressing the α-lactalbumin protein. The company plans to license lira-cel to a large pharmaceutical company for commercialization. Customers and collaborators mentioned include Cleveland Clinic, Moffitt Cancer Center, and Wistar.
Sources:
Anixa Biosciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Anixa Biosciences Inc’s corporate clients.
For your research, we’ve provided 9 tables on Anixa Biosciences Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
